S2Medical AB (S2M) - Net Assets
Based on the latest financial reports, S2Medical AB (S2M) has net assets worth Skr18.88 Million SEK (≈ $2.03 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr25.96 Million ≈ $2.79 Million USD) and total liabilities (Skr7.08 Million ≈ $762.14K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read S2Medical AB debt and liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr18.88 Million |
| % of Total Assets | 72.72% |
| Annual Growth Rate | 75.28% |
| 5-Year Change | -32.72% |
| 10-Year Change | 259.03% |
| Growth Volatility | 2236.11 |
S2Medical AB - Net Assets Trend (2015–2025)
This chart illustrates how S2Medical AB's net assets have evolved over time, based on quarterly financial data. Also explore S2Medical AB balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for S2Medical AB (2015–2025)
The table below shows the annual net assets of S2Medical AB from 2015 to 2025. For live valuation and market cap data, see S2M company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr9.88 Million ≈ $1.06 Million |
-16.31% |
| 2024-12-31 | Skr11.80 Million ≈ $1.27 Million |
+611.84% |
| 2023-12-31 | Skr1.66 Million ≈ $178.42K |
-76.55% |
| 2022-12-31 | Skr7.07 Million ≈ $760.76K |
-51.85% |
| 2021-12-31 | Skr14.68 Million ≈ $1.58 Million |
-55.19% |
| 2020-12-31 | Skr32.77 Million ≈ $3.53 Million |
+30.48% |
| 2019-12-31 | Skr25.11 Million ≈ $2.70 Million |
-42.33% |
| 2018-12-31 | Skr43.55 Million ≈ $4.69 Million |
+490.48% |
| 2017-12-31 | Skr7.38 Million ≈ $793.67K |
+168.08% |
| 2016-12-31 | Skr2.75 Million ≈ $296.05K |
+7531.49% |
| 2015-12-31 | Skr36.05K ≈ $3.88K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to S2Medical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11317004800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.57 Million | 15.94% |
| Other Components | Skr121.49 Million | 1230.00% |
| Total Equity | Skr9.88 Million | 100.00% |
S2Medical AB Competitors by Market Cap
The table below lists competitors of S2Medical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Panthera Resources PLC
LSE:PAT
|
$612.46K |
|
Gyldendal A/S
CO:GYLD-B
|
$612.74K |
|
Oxbridge Re Holdings Equity Warrant
NASDAQ:OXBRW
|
$614.64K |
|
Ivory Properties Group Bhd
KLSE:5175
|
$615.21K |
|
EPE Special Opportunities Limited
LSE:ESO
|
$611.68K |
|
Cora Gold Limited
LSE:CORA
|
$611.12K |
|
Panther Securities P L C
LSE:PNS
|
$610.56K |
|
Ortel Communications Limited
NSE:ORTEL
|
$609.84K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in S2Medical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,802,000 to 9,877,000, a change of -1,925,000 (-16.3%).
- Net loss of 10,092,000 reduced equity.
- Other factors increased equity by 8,167,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-10.09 Million | -102.18% |
| Other Changes | Skr8.17 Million | +82.69% |
| Total Change | Skr- | -16.31% |
Book Value vs Market Value Analysis
This analysis compares S2Medical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.59x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.09x to 0.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr0.08 | Skr0.01 | x |
| 2017-12-31 | Skr0.29 | Skr0.01 | x |
| 2018-12-31 | Skr0.94 | Skr0.01 | x |
| 2019-12-31 | Skr0.54 | Skr0.01 | x |
| 2020-12-31 | Skr0.71 | Skr0.01 | x |
| 2021-12-31 | Skr0.25 | Skr0.01 | x |
| 2022-12-31 | Skr0.10 | Skr0.01 | x |
| 2023-12-31 | Skr0.01 | Skr0.01 | x |
| 2024-12-31 | Skr0.02 | Skr0.01 | x |
| 2025-12-31 | Skr0.01 | Skr0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently S2Medical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -102.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -70.27%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 1.70x
- Recent ROE (-102.18%) is above the historical average (-202.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 7.76% | 0.18% | 0.44x | 96.96x | Skr-808.80 |
| 2016 | -43.44% | -351.47% | 0.05x | 2.34x | Skr-1.47 Million |
| 2017 | -72.91% | -637.09% | 0.08x | 1.51x | Skr-6.11 Million |
| 2018 | -24.64% | -717.50% | 0.03x | 1.13x | Skr-15.09 Million |
| 2019 | -73.41% | -595.00% | 0.10x | 1.22x | Skr-20.95 Million |
| 2020 | -46.03% | -58.88% | 0.62x | 1.26x | Skr-18.36 Million |
| 2021 | -136.77% | -260.78% | 0.26x | 2.02x | Skr-21.55 Million |
| 2022 | -416.69% | -630.73% | 0.18x | 3.58x | Skr-30.16 Million |
| 2023 | -1369.60% | -325.73% | 0.33x | 12.91x | Skr-22.87 Million |
| 2024 | 48.90% | 38.72% | 0.82x | 1.53x | Skr4.59 Million |
| 2025 | -102.18% | -70.27% | 0.86x | 1.70x | Skr-11.08 Million |
Industry Comparison
This section compares S2Medical AB's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $292,928,889
- Average return on equity (ROE) among peers: -44.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| S2Medical AB (S2M) | Skr18.88 Million | 7.76% | 0.38x | $611.88K |
| ADDvise Group AB A (ADDV-A) | $3.30 Million | 33.40% | 2.57x | $4.23 Million |
| ADDvise Group B (ADDV-B) | $835.00 Million | 10.78% | 3.13x | $108.58 Million |
| AddLife AB (publ) (ALIF-B) | $346.60 Million | 22.45% | 2.68x | $1.80 Billion |
| Biotage AB (BIOT) | $990.04 Million | 17.68% | 0.45x | $1.23 Billion |
| Bonesupport Holding AB (BONEX) | $34.30 Million | -321.22% | 4.50x | $1.56 Billion |
| Dynavox Group (DYVOX) | $139.50 Million | 21.36% | 7.22x | $930.88 Million |
| iZafe Group AB Series B (IZAFE-B) | $40.73 Million | -89.06% | 0.19x | $14.83 Million |
| Ortivus AB ser. A (ORTI-A) | $22.41 Million | -97.60% | 2.16x | $322.08K |
| Ortivus AB ser. B (ORTI-B) | $224.47 Million | 5.79% | 0.15x | $14.04 Million |
About S2Medical AB
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and… Read more